GlassScriptPhysician profile
Samantha Ramirez
NPI 1205480449
$18,875.13
in general payments reported to CMS, 2019-2025
11 companies · $5,361 in 2025
The $5,361 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $921 · 2022: $474 · 2023: $4,768 · 2024: $7,351 · 2025: $5,361.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $9,000 · Food and Beverage: $3,566 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $2,475 · Travel and Lodging: $2,342 · Education: $96.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $9,000.00 |
| Food and Beverage | $3,566.07 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $2,475.00 |
| Travel and Lodging | $2,342.42 |
| Education | $96.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15,487.33 | 2021-2025 | Xifaxan, Trulance, Relistor |
| Gilead Sciences, INC. | $1,280.55 | 2021-2025 | Livdelzi, Epclusa |
| Madrigal Pharmaceuticals | $727.50 | 2024-2025 | Rezdiffra, Resmetirom |
| Dova Pharmaceuticals | $294.88 | 2021 | |
| Abbvie INC. | $263.24 | 2021-2023 | |
| Ipsen Biopharmaceuticals, INC | $243.46 | 2024-2025 | Iqirvo |
| Intercept Pharmaceuticals, INC. | $189.53 | 2022-2023 | Ocaliva |
| Sobi, INC | $112.46 | 2022 | |
| Eisai INC. | $100.00 | 2021 | |
| Novo Nordisk INC | $96.81 | 2025 | |
| Calliditas Therapeutics US INC. | $79.37 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samantha Ramirez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.